In an adoptive transfer therapeutic strategy in mice, ablating STAT3 in CD8+ T-cells prior to transfer, allows efficient tumor infiltration and robust CD8+ T-cell proliferation, resulting in increased tumor antigen-specific T-cell activity and tumor growth inhibition [61]. The gene discussed is STAT3; the disease is neoplasm.